Press

Press releases
News

Calmark receives additional order from Italy

Calmark Sweden AB (publ) announces today that the Company has received an additional order from the distributor in Italy, P.R.I.S.M.A. Srl (Prisma) covering the Calmark Neo platform.
Read more
News

Calmark modifies its communication policy relating to sales and orders

To enhance transparency in respect of the launching and sales of Calmark’s products, the Company announces a modification of the communication policy.
Read more
News

Calmark Neo-Bilirubin receives UNICEF’s quality seal "NEST360 Qualified"

Calmark Sweden AB announced today that the company's diagnostics for jaundice, Neo-Bilirubin, meets the characteristics for products in low-income countries, developed by the organization NEST360 in collaboration with UNICEF. The award shows that Calmark's product is efficient, affordable, robust and easy to use.
Read more
Press releases

Calmark signs distributor agreement with MTTS for Vietnam, Cambodia and Laos

Calmark Sweden AB (publ) has today entered an exclusive distributor agreement with the company MTTS Co., Ltd regarding marketing and sales of Calmark's Neo products in the countries Vietnam, Cambodia and Laos. Through this agreement, Calmark expands its launch in Asia, where there is an extensive need for safe and effective diagnostics.
Read more

Calmark receives order from Greece for Neo-Bilirubin

Calmark Sweden AB (publ) announces today that an order has been received from the Company's distributor in Greece, Prime Biosciences, for the Neo products. Today’s order is of less economic importance, but significant in a launch perspective.
Read more
Press releases

Calmark signs distributor agreement with Prime Biosciences in Greece

Calmark Sweden AB (publ) has entered an exclusive distributor agreement with the company Prime Biosciences regarding marketing and sales of the Calmark POC system on the Greek market.
Read more
News

Calmark receives patent number for granted patent in the United States

Calmark Sweden AB (publ) has received announcement from the US Patent Office ("USPTO") regarding a granted patent covering the Calmark POC system and the method of detecting a biomarker in, for example, blood. The patent number is 11255864 and it is valid until April 6, 2039. Advance notice of this was press released on December 8, 2021.
Read more
News

Calmark compliant with IVDR from today

Anna Söderlund, CEO of Calmark Sweden AB (publ) has today signed the ‘Declaration of Conformity’ showing that Calmark has adapted the quality system and the technical documentation to comply with the new IVDR regulations. The documentation will now be sent to the Swedish Medical Products Agency. Compliance with the IVDR is a requirement to maintain the CE marking of existing products from May 26, 2022 onwards.
Read more
News

Calmark's trial at Södersjukhuset completed

Calmark Sweden AB (publ) announces today that the clinical trial with the product Neo-Bilirubin, which commenced in September 2021 in cooperation with the research entity of the children's hospital Sachsska barn- och ungdomssjukhuset, Södersjukhuset AB, Stockholm, is now successfully completed. All patients have been included and all that remains now is to prepare the final report. Monitoring of the trial was conducted by Scandiavian CRO.
Read more
Press releases

Calmark's distributor in India also signs agreements for the Neo products

Calmark Sweden AB announced today that an exclusive distributor agreement has been signed with r2 Diagnostics in India regarding Calmark's test for newborns.
Read more
Press releases

Calmark receives order from Italy regarding Neo-products

Calmark Sweden AB (publ) announces today that the Company has received an order from the distributor in Italy, P.R.I.S.M.A. Srl (Prisma) covering the Calmark Neo platform. The economic value of today's order is of minor importance, but it is important from a launch perspective.
Read more
News

Calmark re-prioritizes resources to focus on sales of existing products

Calmark Sweden AB announced today that it has resolved to re-prioritize resources, which entails that the timetable for the development project relating to Neo-LDH is updated; the product will not obtain CE marking before May 26.
Read more
Press releases

Calmark's distributor in Italy also signs agreements for the Neo products

Calmark Sweden AB announced today that an exclusive distributor agreement has been signed with P.R.I.S.M.A. Srl (Prisma) in Italy regarding Calmark's test for newborns.
Read more
News

Calmark’s test Neo-LDH enters verification and validation phase to obtain CE mark

Calmark Sweden AB (publ) announces today that the development project for the Company's product for newborns, Neo-LDH, is now progressing to verification and validation. This phase, which is one of the final elements of the process, is estimated to last for approximately two months. When it is completed, regulatory documentation will be compiled in order to achieve the CE Mark approval.
Read more
News

Calmark presents at Stockholm Corporate Finance 14th Life Science seminar, Capital Markets Day, 2022

Calmark attends Stockholm Corporate Finance 14th Life Science seminar that will be held on March 8 - 9, 2022. The event is carried out both physically at IVA in Stockholm and digitally in real time. CEO Anna Söderlund presents the latest developments and the future prospects for the company at 10:00 on March 9. The presentation is held in Swedish.
Read more
Press releases

Calmark receives order from the United Arab Emirates

Calmark Sweden AB (publ) announces today that the Company has received an order from the distributor in the United Arab Emirates (UAE), Enox Pharma AB, covering both the Calmark Neo platform and Calmark Covid platform. The economic value of today's order is of minor importance, but it is important from a launch perspective.
Read more
News

Calmark strengthens logistics and order processing in preparation of global launch

Calmark Sweden AB has hired Liana Rikberg for the role as Supply Chain Coordinator in order to strengthen its team for the global launch. Liana will take up position on January 10, 2022.
Read more
Press releases

Calmark's Rights issue registered – conversion of BTA B to B shares

Calmark Sweden AB (publ) (“Calmark” or ”the Company”) has carried out a rights issue of B shares to an amount of approximately MSEK 24.9 (“the Rights Issue”). The Rights Issue was completed on November 23, 2021. The Rights Issue was subscribed to 137.3 percent.
Read more
News

Calmark receives Notice of Allowance regarding patent in USA

Calmark Sweden AB (publ) announces today that the US Patent Office ("USPTO") has issued a Notice of Allowance regarding Calmark's POC system.
Read more
Press releases

Firyal Kryou new CFO for Calmark

Calmark Sweden AB (publ) announces today that the company has contracted Firyal Kryou as interim CFO and member of the management team. She will take up the role today, December 1, 2021.
Read more
Press releases

Final subscription rate of rights issue in Calmark Sweden AB (publ) amounts to 137.3 percent

The Rights Issue of approximately MSEK 24.9 in Calmark Sweden AB (publ) (“Calmark” or "the Company”), which was announced on 22 October 2021, (“the Rights Issue”) was oversubscribed. The final subscription rate of the Rights Issue was 137.3 percent. The Rights Issue provides the Company approximately MSEK 24.9 in proceeds before issuance costs.
Read more
Press releases

Preliminary subscription rate of rights issue in Calmark Sweden AB (publ) amounts to approximately 137 percent

The preliminary outcome of the rights issue in Calmark Sweden AB (publ) (“Calmark” or “the Company”), the subscription period of which ended at 3:00 p.m. today, 23 November 2021, indicates a subscription rate of 137.2 percent. Through the rights issue, Calmark will receive the maximum amount of MSEK 24.9 before issuance costs, approximately MSEK 2.5.
Read more
Press releases

The directed issue to Gainbridge Capital is now registered

Calmark Sweden AB (publ) announces today that the directed issue of 388,936 B shares to Gainbridge Capital now has been registered. The issue was carried out at a subscription price of SEK 5.40 per B share, raising approximately MSEK 2.1 before issuance costs and increasing the share capital by SEK 38,893.60.
Read more
Press releases

Calmark Sweden AB (publ) publishes information memorandum in view of rights issue

The Board of Directors of Calmark Sweden AB (publ) (“Calmark” or “the Company”) announces today that the information memorandum in view of the Company's previously announced rights issue (“the Rights Issue”) has been approved by Spotlight Stock Market. The information memorandum and other relevant information will be made available on the Company’s website, www.calmark.se, on Hagberg & Aneborn Fondkommission AB’s website, www.hagberganeborn, and on Spotlight Stock Market’s website, www.spotlightstockmarket.com.
Read more
News

Calmark presents at Redeye Life Science Day 2021

Calmark attends the digital event Redeye Life Science Day 2021 that will be held on November 11. CEO Anna Söderlund presents the latest developments and the future prospects for the company at 11:20. The presentation is held in Swedish and will be broadcast live.
Read more
News

Redeye publishes research update on Calmark

Analyst firm Redeye has today published a research update: "Calmark: Untapped Potential".
Read more
Press releases

Calmark brings forward publication of interim report for Q3

Calmark Sweden AB (publ) announces today that the publication of the interim report for the third quarter of 2021 will be further brought forward to 29 October.
Read more
Press releases

The Board of Directors of Calmark Sweden AB (publ) resolves to carry out a rights issue of approx. MSEK 24.9 and a directed issue of approx. MSEK 2.1, and brings forward the interim report for Q3 2021

The Board of Directors of Calmark Sweden AB (publ) (“Calmark” or the “Company”) has, on the authority of the Annual General Meeting of 18 May 2021, resolved on a rights issue of not more than 4,611,064 B shares, with preferential rights for existing shareholders in Calmark (the “Rights issue”). The Company has obtained subscription commitments corresponding to approximately 54 percent of the Rights Issue from, inter alia, Wingefors Invest AB and Creades AB (via capital insurance), as well as guarantee commitments corresponding to approximately 26 percent of the Rights Issue from Gainbridge Capital AB (“Gainbridge Capital”) and a number of existing owners. In total, the subscription and guarantee commitments correspond to approximately 80 percent of the Rights Issue. Provided that the Rights issue is fully subscribed, the Company will raise proceeds of approximately MSEK 24.9 before issuance costs. In addition, the Board of Directors of Calmark has, on the authority of the Annual General Meeting of 18 May 2021, resolved on a directed issue of 388,936 B shares to Gainbridge Capital, corresponding to approximately MSEK 2.1 (the “Directed Issue”). In view of the new share issues, Calmark advances the publication of the interim report for the third quarter to 5 November 2021.
Read more
Press releases

Calmark intensifies efforts in India

Calmark Sweden AB (publ) (“Calmark” or “the Company”) announces today that it will intensify efforts in relation to the market launch in India, and that the potential is considered to be significant. The Company has supplied India with instruments and COVID19-LDH tests in view of a possible procurement.
Read more
Press releases

Calmark receives order from Switzerland

Calmark Sweden AB (publ) announces today that the Company has received an order from the distributor in Switzerland, LabForce AG, covering the Calmark Neo platform and bilirubin tests. The economic value of today's order is of minor importance, but it is important from a launch perspective.
Read more
News

Clinical study for Neo-Bilirubin started at Sachsska Children's Hospital

Calmark Sweden AB (publ) announces today that a new clinical study regarding Neo-Bilirubin has been started in cooperation with the research unit at children's hospital Sachsska barnsjukhuset, part of Södersjukhuset AB, Stockholm.
Read more

Calmark receives order from Egypt

Calmark Sweden AB (publ) announces today that the Company has received an order from the distributor in Egypt, Enox Pharma AB, covering the Calmark Neo platform and bilirubin tests. The economic value of today's order is of minor importance, but it is important from a launch perspective.
Read more
Press releases

Calmark receives order from Iraq

Calmark Sweden AB (publ) announces today that the Company has received an order from the distributor in Iraq, Enox Pharma AB, covering the Calmark Neo platform and bilirubin tests. The economic value of today's order is of minor importance, but it is important from a launch perspective.
Read more
News

Calmark's COVID-19 instrument has been registered in India

Calmark Sweden AB's instrument, used to measure LDH levels in COVID-19 patients, has been registered by the Indian authorities. Associated tests are still under registration process. Registration of medical devices is mandatory before the sales start.
Read more
Press releases

Calmark’s fully automated production line has been installed and the first batches of test cassettes produced

Calmark Sweden AB (publ) announces today that all the steps in the process validation of the fully automated production line have been completed and the first batches of test cassettes produced with good results.
Read more
Press releases

The English Edition of Calmark’s Annual Report 2020 is published

Calmark Sweden AB’s Annual Report 2020 is now available also in English
Read more
Press releases

Calmark signs distributor agreement for India regarding COVID19-LDH

Calmark Sweden AB (publ) has entered an exclusive distributor agreement with the company r2 Hemostasis Diagnostics India Private Ltd regarding marketing and sales of the Calmark POC - Covid platform in the Indian market.
Read more
News

Calmark receives order from Jordan

Calmark Sweden AB (publ) announces today that the Company has received an order from the distributor in Jordan, Alpha Tech Est., covering the Calmark Neo platform and bilirubin tests.
Read more
News

Calmark’s Italian distributor places order for COVID19-LDH demo units

Calmark Sweden AB (publ) announces today that an order has been received from the Company’s Italian distributor P.R.I.S.M.A. Srl (Prisma).
Read more
News

Calmark’s fully automated production line completed, installation commences

Calmark Sweden AB (publ) announces today that the new production line has passed the Factory Acceptance Test (FAT), and the FAT protocol has been signed. This means that the line is now completed and will be moved from Automationspartner in Ramlösa to Calmark’s production partner Frohe AB in Tyresö.
Read more
News

Start-up of new clinical trials put on hold at Sachsska barnsjukhuset

Calmark Sweden AB (publ) announces today that new clinical trials in cooperation with the research unit at the children's hospital Sachsska barnsjukhuset, part of Södersjukhuset AB, Stockholm, will not be able to start in the coming months. The reason is that resources must be re-prioritized due to the situation with COVID-19. Further notice is expected.
Read more
Press releases

Calmark CE marks product for assessing COVID-19 severity

Calmark Sweden AB (publ) announces today that the product Calmark COVID19-LDH has obtained its CE marking in accordance with the IVD directive. The product is now ready for sale and use in healthcare, including in the EU.
Read more
News

Calmark informs about transfer of shares

Calmark Sweden AB today announces that the board member and co-founder Mathias Karlsson, through his company Valetudor Development AB, has transferred 113,334 Series B shares to Wingefors Invest AB to settle loans. The price per share amounts to SEK 7.50, a total of SEK 850,005 for all the shares. The loans were raised by Mathias Karlsson to acquire Calmark shares in connection with the 2018 listing on Spotlight Stock Market.
Read more
Press releases

Updated timetable regarding Calmark's LDH test for Covid-19 assessment

Calmark Sweden AB announces today that the timetable for the development project related to the product COVID19-LDH has been updated. The CE marking of this POC test will take place one to two weeks later than previously disclosed.
Read more
Press releases

Calmark signs distributor agreement with Enox Pharma for five key markets in the Middle East

Calmark Sweden AB (publ) has today entered an exclusive distributor agreement with the company Enox Pharma AB regarding marketing and sales of Calmark's products in the countries Egypt, Iraq, Bahrain, Saudi Arabia and the United Arab Emirates. Through this agreement, Calmark expands its launch in the MENA region, where there is an extensive need for safe and effective diagnostics.
Read more
News

Calmark presents in the webinar “Strategic Routes for Entering the Chinese Life Science Market”

As a company that has recently entered the Chinese market, Calmark will share its experiences, tips and tricks so far, at the third China webinar hosted by the Swecare Foundation. The webinar will be held on 18 March at 8:30.
Read more
News

Calmark strengthens sales and marketing team in preparation of global launch

Calmark Sweden AB has hired Maria Zavodnik for the role as Sales and Marketing Coordinator in order to strengthen its team for the global launch. Maria will take up position on March 24, 2021.
Read more
News

Calmark’s subsidiary in Wuxi, China, is now registered

Calmark Sweden AB (publ) announces today that the registration of the subsidiary in mainland China has been approved by local authorities. The name of the new company is 凯曼克医疗器械(无锡)有限公司 (Calmark Med-tech (Wuxi) Limited company).
Read more
News

Calmark's LDH test for assessment of COVID-19 enters the verification and validation phase of the CE marking process – analytical results are within the expected range

Calmark Sweden AB (publ) announces today that the development project for the Company's product COVID19-LDH now moves to verification and validation. This phase is one of last steps in the process, with an estimated duration of approximately five weeks. Thereafter, the product will move into production, and CE mark certification can take place.
Read more
News

Calmark participates in Swiss Nordic Bio 2021 on 10-11 February

Anna Söderlund, CEO at Calmark will participate at Swiss Nordic Bio 2021, which will be held in digital format with more than 300 participants and 100 investors. The event will be live streamed and 1-to-1 meetings will be held virtually.
Read more
News

Calmark strengthens QA, recruits Annika Kaisdotter Andersson as International Quality Manager

Calmark Sweden AB has hired Annika Kaisdotter Andersson for the role as International Quality Manager in order to strengthen its QA/RA capabilities. Annika is currently working as Global Head of Quality Assurance in the ABB group. She will work on Calmark’s quality management system and product registrations together with Michael Lundh, who joined the team last summer.
Read more
Press releases

Calmark receives SEK 10.7 million through the redemption of warrants with an exercise rate of 98.1%

Calmark Sweden AB (publ) (“Calmark” or “the Company”) carried out a rights issue of shares and free-of-charge warrants during November 2019. The exercise period of the Series TO 2 B subscription warrants was between December 4, 2020, and December 16, 2020, and thus has ended. In total, 2,408,005 TO 2 B warrants were used to subscribe for shares, corresponding to an exercise rate of approximately 98.1 percent.
Read more
News

Calmark signs distributor agreement with LabForce in Switzerland

Calmark Sweden AB (publ) has entered an exclusive distributor agreement with the company LabForce AG regarding marketing and sales of the Calmark POC system on the Swiss market.
Read more
News

Last day of trading in Series TO 2 B subscription warrants

The exercise period of the Series TO 2 B subscription warrants issued in connection with the rights issue of units that Calmark Sweden AB (publ) carried out during November 2019 runs until and including December 16, 2020. The last day of trading in Series TO 2 B subscription warrants on Spotlight Stock Market is December 14, 2020. Holders of Series TO 2 B subscription warrants are entitled, for each warrant, to subscribe for one new B share in Calmark at a price of SEK 4.44 per B share. On full exercise of all Series TO 2 B subscription warrants, 2,455,560 new B-shares will be issued, and Calmark will raise approximately MSEK 10.9 before issuance costs.
Read more
News

Calmark signs distributor agreement with ILS Danmark

Calmark Sweden AB (publ) has entered an exclusive distributor agreement with the company ILS Danmark regarding marketing and sales of the Calmark POC system on the Danish market. The agreement provides Calmark with an additional well-established partner on the important domestic market.
Read more
News

Calmark signs distributor agreement with Bergman Diagnostika in Norway

Calmark Sweden AB (publ) has entered an exclusive distributor agreement with the company Bergman Diagnostika AS, part of the Triolab Group, regarding marketing and sales of the Calmark POC system on the Norwegian market. The agreement provides Calmark with an additional well-established partner on the important domestic market.
Read more
News

Calmark certified according to ISO 13485:2016

Calmark Sweden AB has carried out a certification of its quality management system in accordance with ISO 13485:2016. Review and certification were conducted by RISE Research Institutes of Sweden AB.
Read more
Press releases

Calmark's issue heavily oversubscribed - raises MSEK 26.5

The Board of Directors of Calmark Sweden AB ("Calmark" or "the Company") has, conditional on the approval of the Extraordinary General Meeting and in accordance with what was disclosed in the Company's press release earlier today, resolved to conduct a directed new issue of 5,000,000 shares at a subscription price of SEK 5.30 per share ("the Directed Issue"). The Directed Issue was subscribed by a number of existing and external private investors and family offices, including Wingefors Invest AB and Creades AB.
Read more
Press releases

Calmark explores the feasibility of carrying out a directed issue of shares

Calmark Sweden AB ("Calmark" or "the Company") has instructed Erik Penser Bank to explore the feasibility of carrying out a directed new issue of approximately SEK 20 million (the “Directed issue”) by means of an accelerated book building process ("the Book Building Process"). The Directed Issue will be conditional on the subsequent approval of an extraordinary general meeting, which is planned to be held on December 23, 2020.
Read more
News

Major owners and key people at Calmark intend to redeem warrants

Today, on December 7, 2020, Calmark Sweden AB (publ) ("Calmark") announces that persons on Board of Directors, executive management and major owners have made statements of intent to exercise their respective subscription warrants. The statements cover the subscription of approximately 911,548 shares at a subscription price of SEK 4.44, corresponding to approximately MSEK 4,047,273.12. This means that the exercise of about 37 percent of the warrants now has been pre-agreed through declarations of intent.
Read more
Press releases

The exercise period for Calmark’s subscription warrants begins today

During November 2019, Calmark Sweden AB (publ) ("Calmark" or "the Company") carried out a rights issue of units, consisting of shares and series TO 2 B subscription warrants. On Friday, December 4, 2020, the exercise period for the series TO 2 B subscription warrants begins. The subscription period will continue until December 16, 2020.
Read more
Press releases

Calmark signs distributor agreement in Italy

Calmark Sweden AB announced today that an exclusive distributor agreement has been signed with P.R.I.S.M.A. Srl (Prisma) in Italy. The agreement covers Calmark's test for assessment of COVID-19 disease severity and contains a minimum contract volume of EUR 457 500. The test, "Calmark COVID-19-LDH", is under development and is projected to obtain its CE mark approval during the first quarter of 2021, after which it will be ready for sale.
Read more
Press releases

Calmark enters into cooperation with VIA Global Health to accelerate globalization

Calmark Sweden AB today announced that an agreement regarding distribution of the Company's products has been signed with the U.S. company VIA Global Health, which specializes in distribution of medical devices in low- and middle-income countries. The agreement entails that Calmark's products can reach out to countries in, e.g., Africa and South America sooner than anticipated, and more cost-efficiently.
Read more
Press releases

Calmark Sweden AB locates Chinese mainland office to Wuxi, outside Shanghai

Calmark Sweden AB today announced that a new decision has been made regarding the location of the Company's office in mainland China. Following financial negotiations, the alternative to locate the office to Wuxi, outside Shanghai, appears more advantageous than the previously disclosed location, the Greater Bay Area.
Read more
News

Calmark presents at Redeye Life Science Day 2020

Calmark attends the digital event Redeye Life Science Day 2020 that will be held on November 26. CEO Anna Söderlund presents the latest developments and the future prospects for the company at 9:30. The presentation is held in Swedish and will be broadcast live.
Read more
News

Redeye publishes initial coverage on Calmark

Analyst firm Redeye has today published the report "Calmark: Diagnosing the New Generation".
Read more
News

Calmark recruits Michael Lund to key position as QA/RA Director

Calmark Sweden AB has hired Michael Lund who will assume position as Quality Assurance and Regulatory Affairs Director, a role which he has held on a consultancy basis since 2016. Michael is part of Calmark's management team and is responsible for project management and quality assurance of the product development, as well as certification and registration of the products in different markets.
Read more
Press releases

Calmark receives order from Triolab Finland - clarification

Clarification: Calmark Sweden AB's press release from today at 14:00 regarding order from Triolab Finland is of strategic importance as it shows that Calmark's distributor has now started demonstrations and active sales work. The economic value of the order is of minor importance.
Read more

Calmark receives order from Triolab Finland

Calmark Sweden AB has today received an order for the Calmark Neo platform, comprising Calmark's instrument as well as tests for bilirubin. The order was placed by Triolab Oy, which is Calmark's exclusive distributor in Finland, Lithuania, Latvia and Estonia.
Read more
News

Calmark's subsidiary in Hong Kong is now registered

Calmark Sweden AB today announces that the Company's subsidiary in Hong Kong has been registered. Calmark Hongkong Limited is a wholly-owned subsidiary of the Swedish company. The effort to establish a subsidiary in mainland China continues.
Read more
News

Calmark decides to locate the Chinese subsidiary in Guangzhou, Greater Bay Area

An exploratory review has led Calmark to the conclusion that the Greater Bay Area will be the most suitable location for Calmark's subsidiary in mainland China. The city of Guangzhou, situated as it is and harboring a cluster of MedTech companies, has now been selected for the next phase.
Read more

Calmark receives its first order from Triolab AB in Sweden

Calmark Sweden AB has today received the Company's first order for the Calmark Neo platform. The order covers both the reader and test cassettes for bilirubin, and was placed by Triolab AB, which is Calmark's exclusive distributor in Sweden.
Read more
Press releases

Calmark signs distributor agreement in Jordan

Calmark Sweden AB has today signed an exclusive distributor agreement with the company Alpha Tech Est. in Amman, Jordan.
Read more
Press releases

Calmark's LDH test for assessment of COVID-19 disease severity is estimated to be ready for launch in Q1 2021

Calmark Sweden AB announces today that the product development of an LDH test for assessment (triage) of COVID-19 is proceeding according to plan; the test is now projected to obtain CE conformity marking in Q1 2021. The project has now successfully completed the chemical impregnation in Calmark's recently installed BioDot machine, which will be used in the production line.
Read more
Press releases

Calmark Sweden is granted two new patents

Calmark Sweden AB has been granted two new patents, one concerning the technical construction of the single-use item and one concerning the method of reading bilirubin. These will be published in the Swedish Patent Gazette No. 2020/39, on 2020-09-22. The patents are numbered 543 001 and 543 002.
Read more
News

Calmark recruits Jim Hansson for the role as Director of Production & Logistics

Calmark Sweden AB has hired Jim Hansson who will assume position as Director of Production & Logistics. Jim will be responsible for the development of Calmark's production and logistics, and will take office in October 2020.
Read more
News

Calmark hires Camilla Arneving as Marketing Director

Calmark Sweden AB has recruited Camilla Arneving for the role as Marketing Director, a position that she has held on an interim basis for almost two years. Camilla is part of Calmark's management team and is responsible for communication and marketing to distributors, health care and other stakeholders.
Read more
Press releases

Calmark establishes cooperation with Nordic Match on Chinese expansion

Today, Calmark Sweden AB has resolved to initiate a cooperation with Nordic Match, a boutique M&A and Strategy Advisor for Sino-Nordic transactions. The cooperation covers the Chinese market entry for Calmark and the planning of a joint venture. The project will commence during summer and the expected project duration is approximately 18 months. Calmark thus advances the launch in China by about two years.
Read more
Press releases

Calmark is developing a POC-test to help assess disease severity for patients with COVID-19 patients

The Board of Directors of Calmark Sweden AB has today resolved to develop a diagnostic point-of-care (POC) test for the lactate dehydrogenase biomarker (LDH) aimed at adult patients with COVID-19. Several studies have demonstrated that LDH levels can predict the severity and mortality of the disease. Since the time aspect of COVID-19 products is of paramount importance, this test will be developed in parallel with the tests for newborns; Neo-LDH and Neo-Glucose.
Read more
News

Calmark strengthens the team with a software developer

Calmark Sweden AB has recruited Balázs Szabó in the role of junior software developer. The employment begins on August 17.
Read more
News

Calmark signs agreement regarding equipment for automation of production line

Today, Calmark Sweden AB and Automations Partner i Helsingborg Aktiebolag signed an agreement regarding the construction of the machines for the fully automated production line for the single-use tests.
Read more
News

Calmark recruits Director of International Business Development to develop global growth strategies

Calmark Sweden AB has signed an agreement with Magdalena Tharaldsen, who will be the company's new Director of International Business Development. Magdalena will be part of Calmark's Management Team and assumes responsibility for building the wide network of distributors that will provide the framework for Calmark's sales strategy.
Read more
Press releases

Calmark signs distributor agreement with Triolab regarding more markets

Calmark Sweden AB (publ) has entered an exclusive distributor agreement with the company Triolab Oy regarding marketing and sales of the Calmark Neo platform in Finland, Estonia, Latvia and Lithuania. Triolab already has an exclusive right to distribute Calmark's products in Sweden. The agreement means that Calmark expands its network of partners on the important domestic market.
Read more
News

The English Edition of Calmark’s Annual Report 2019 is published

Calmark Sweden AB’s Annual Report 2019 is now available also in English
Read more
Press releases

Calmark's first product, Neo-Bilirubin, obtains CE Mark

Calmark Sweden AB (publ) announces today that the product Calmark Neo-Bilirubin has obtained its CE marking in accordance with the IVD directive. The product can now be sold to and used in healthcare within the European Union.
Read more
Press releases

Calmark brings investment in production line forward

The Board of Directors of Calmark Sweden AB has today resolved to bring the final step of the automation of the production line for the single-use item forward, to build the last two steps in parallel. The Company has concluded an agreement with SEB, Skandinaviska Enskilda Banken AB (publ), relating to leasing of the production equipment.
Read more
Press releases

Calmark's trial at Södersjukhuset closed

The clinical trial with Calmark's first product, Neo-Bilirubin, which has been carried out by the research unit at the children's hospital Sachsska barnsjukhuset, part of Södersjukhuset AB, Stockholm, is now successfully closed with satisfactory results. Monitoring of the trial was conducted by Scandiavian CRO. The remaining step before Neo-Bilirubin can obtain its CE mark is the preparation of final reports, which is projected to take approximately two weeks.
Read more
News

Calmark's Board of Directors proposes that a new Chairman of the Board be elected by the AGM

Ahead of the Annual General Meeting, which will be held on 14 May, the Board of Directors proposes that Kjersti Berg Marthinsen be elected to replace the founder Mathias Karlsson as the Chairman of the Board of Calmark. Mathias Karlsson will remain on the board and leads the Medical Advisory Board of the Company.
Read more
Press releases

Calmark comments on the effects from COVID-19 and announces updated timetable for clinical trial at Södersjukhuset

Calmark Sweden AB announces today that the timetable for the clinical trial at Södersjukhuset with the Company's first product, Neo-Bilirubin, has been updated. All infants have still not been included, and given the current circumstances, it is difficult to predict when it will be possible to finish the study. Nevertheless, the work is progressing at the best possible pace. Once the last infant has been included, the remaining step before Neo-Bilirubin can obtain its CE mark is the preparation of final reports, which is projected to take approximately two weeks.
Read more
Press releases

Verification phase for Calmark's first product completed

The verification phase of the development project for Calmark Sweden AB's (publ) first product, Neo-Bilirubin, was completed today with successful results from all sub-phases regarding the function and performance of the product.
Read more
News

Calmark presents at Stockholm Corporate Finance 12th Life Science seminar

Calmark attends Stockholm Corporate Finance 12th Life Science Seminar that will be held at Berns on March 11 - 12, 2020. CEO Anna Söderlund presents the latest developments and the future prospects for the company at 10:45 on March 12. The presentation is held in Swedish at Berns and will also be broadcast live at the same time.
Read more
Press releases

Market making agreement terminated - distribution requirement met

First day of trading without the liquidity guarantee is 1 April, 2020.
Read more
Press releases

Calmark signs distributor agreement with Triolab

Calmark Sweden AB (publ) has entered an exclusive distributor agreement with the company Triolab AB regarding marketing and distribution of the Neo Calmark platform on the Swedish market. The agreement provides Calmark with a large and well-established partner on the important domestic market.
Read more
Press releases

Updated timetable for the glucose and LDH products

Calmark Sweden AB announces today that the timetable for the development projects related to the products Neo-Glucose and Neo-LDH have been updated. These products will receive their CE conformity markings during the second quarter at the earliest, not during the first quarter as previously disclosed. The Company has prioritized its resources in order to finalize the CE marking of the first product, Neo-Bilirubin, which is projected to be achieved during the first quarter of 2020.
Read more
News

Calmark strengthens management team, recruits experienced CFO

As part of Calmark Sweden AB's continued strengthening of the organization in view of market and sales launch, Marielle Bos has been recruited for the role as CFO. Up until now, this position has been filled on an interim basis.
Read more
News

The Calmark Neo platform attracted great attention at Arab Health

During this week, Calmark Sweden AB has participated in the international healthcare and medical exhibition Arab Health in Dubai, United Arab Emirates, where the Company made contact with many prospective cooperation partners. Calmark formed the "Innovation Pavilion by Sweden" together with representatives of a total of 25 Swedish companies, organizations and authorities.
Read more
Press releases

Updated timetable for the clinical trial at Södersjukhuset

Calmark Sweden AB announces today that the timetable for the clinical trial underway at Södersjukhuset has been updated. The first patient was included on 23 December, and the rate of inclusion has thus far been lower than expected. The study is now estimated to be finished within six weeks. As a consequence, the Company's first product, Neo-Bilirubin, will obtain its CE conformity marking during the first quarter instead of in January as previously disclosed. This will not impact the market launch.
Read more
News

The Calmark Neo diagnostics platform will be showcased at the international healthcare and medical exhibition Arab Health

Calmark Sweden AB will participate in the Swedish pavilion at the large international fair Arab Health in Dubai, 27-30 January. With more than 106,000 visitors from 160 countries, Arab Health is one of the world's largest healthcare and medical trade fairs. Calmark will be there to showcase its point-of-care (POC) diagnostics platform, Calmark Neo, and to make contact with prospective customers and distributors.
Read more
Press releases

Calmark is granted design protection for the single-use item in the EU and the US

The World Intellectual Property Organization (WIPO) has announced that Calmark Sweden AB has been granted registration of the design in the EU and the US for the company’s unique single-use item.
Read more
Press releases

Calmark's Rights Issue registered – paid subscription units (BTU) are converted to shares and subscription warrants, and trading of subscription warrants commences

Calmark Sweden AB ("Calmark" or "the Company") has carried out a rights issue of units to an amount of approximately MSEK 24.1. The rights issue was completed on 29 November 2019. The rights issue resulted in subscriptions for a total value of approximately MSEK 34.6, corresponding to a subscription rate of about 142.4 percent. The rights issue is now registered with the Swedish Companies Registration Office. The last day of trading in paid subscription units (BTU) is 3 January 2020. The record date is 8 January 2020; after this day, BTU will be converted to B shares and subscription warrants. The newly issued B shares and subscription warrants are expected to be delivered to the shareholders' securities deposit/vpaccounts on 10 January 2020. Trading of subscription warrants of series TO 2 B on Spotlight Stock Market will commence on 10 January 2020.
Read more